Financial health
- Operating income covered interest expense -3392.1× in the latest year, down from -292.5× 5 years ago.
- The company is unprofitable and has less than a year of cash runway at its current free-cash-flow burn.
9 years of revenue, profit, cash flow and balance-sheet history through FY2025, from SEC filings — with a computed, factual read of the trend. Updated Overview →
| FY | Revenue | Net income | Gross M | Op M | ROE | ROA | FCF | Total debt | Cash |
|---|---|---|---|---|---|---|---|---|---|
| 2025 | — | -$117M | — | — | -73.4% | -60.7% | -$97M | — | $39M |
| 2024 | — | -$117M | — | — | -62.8% | -53.2% | -$93M | — | $56M |
| 2023 | — | -$143M | — | — | -83.8% | -68.8% | -$98M | — | $160M |
| 2022 | — | -$70M | — | — | -23.9% | -21.1% | -$62M | — | $258M |
| 2021 | — | -$62M | — | — | -20.5% | -18.3% | -$64M | — | $278M |
| 2020 | — | -$37M | — | — | -33.4% | -23.8% | -$43M | — | $84M |
| 2019 | — | -$28M | — | — | 46.6% | -34.5% | -$29M | — | $11M |
| 2018 | — | -$9M | — | — | 27.7% | -8.5% | -$19M | — | $9M |
| 2017 | — | -$34M | — | — | 125.3% | -61.2% | -$11M | — | $53M |
| Quarter | Revenue | Net income | Gross M | Op M | ROE | ROA | FCF | Total debt | Cash |
|---|---|---|---|---|---|---|---|---|---|
| Jun '26 | — | -$21M | — | — | -17.8% | -14.4% | -$20M | — | $33M |
| Mar '26 | — | -$20M | — | — | -14.5% | -12.0% | -$22M | — | $36M |
| Dec '25 | — | -$31M | — | — | -19.2% | -15.9% | -$21M | — | $39M |
| Sep '25 | — | -$27M | — | — | -24.6% | -19.1% | -$23M | — | $29M |
| Jun '25 | — | -$31M | — | — | -23.4% | -19.2% | -$27M | — | $35M |
| Mar '25 | — | -$28M | — | — | -17.5% | -14.8% | -$27M | — | $28M |
| Dec '24 | — | -$29M | — | — | -15.4% | -13.0% | -$24M | — | $56M |
| Sep '24 | — | -$30M | — | — | -14.4% | -12.4% | -$22M | — | $105M |
| Jun '24 | — | -$30M | — | — | -12.7% | -11.1% | -$24M | — | $224M |
| Mar '24 | — | -$28M | — | — | -10.8% | -9.6% | -$23M | — | $160M |
| Dec '23 | — | -$29M | — | — | -17.3% | -14.2% | -$24M | — | $160M |
| Sep '23 | — | -$50M | — | — | -25.6% | -21.4% | -$22M | — | $183M |
| Jun '23 | — | -$32M | — | — | -13.6% | -11.7% | -$26M | — | $205M |
| Mar '23 | — | -$31M | — | — | -11.6% | -10.1% | -$26M | — | $232M |
| Dec '22 | — | $45M | — | — | 15.2% | 13.5% | -$25M | — | $258M |
| Sep '22 | — | -$22M | — | — | -6.9% | -6.2% | -$20M | — | $283M |
| Jun '22 | — | -$23M | — | — | -7.7% | -6.8% | -$18M | — | $261M |
| Mar '22 | — | $5M | — | — | 1.5% | 1.4% | $1M | — | $278M |
| Dec '21 | — | -$16M | — | — | -5.2% | -4.7% | -$17M | — | $278M |
| Sep '21 | — | -$14M | — | — | -6.5% | -5.4% | -$17M | — | $192M |
See the revenue and net-income charts above for Adicet Bio, Inc.'s multi-year trend.
As of FY2025, Adicet Bio, Inc. reported — of total debt against $39M of cash; operating income covered interest expense -3392.1×.
In FY2025, gross margin was —, operating margin —, and net margin —.
All figures are extracted from the company’s SEC EDGAR/XBRL filings — 10-K annual reports and 10-Q quarterly reports (use the Annual / Quarterly toggle). Quarterly figures are derived from the as-filed statements (year-to-date amounts are differenced into discrete quarters). Growth rates and ratios are computed by tradmap; nothing here is investment advice.
Source: SEC EDGAR / XBRL (10-K + 10-Q filings) · prices EOD (Databento), corporate-action-adjusted · growth rates, valuation multiples & ratios computed by tradmap. Valuation uses each month-end price against the latest annual filing. Informational only — not investment advice.